2-氯-2,3-o-异亚丙基腺苷酸-5-n-乙基羧酰胺 | 120225-75-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 2-氯-2,3-o-异亚丙基腺苷酸-5-n-乙基羧酰胺
• 中文别名: 2-氯-2'，3'-O-异丙基亚氨腺苷-5'-N-乙基羧酰胺；2-氯-2,3-O-异亚丙基腺苷酸-5-N-乙基羧酰胺
• 英文名称: 2-chloro-2',3'-O-isopropylideneadenosine-5'-N-ethylcarboxamide
• 英文别名: 2-chloro-adenosine-5'-N-ethyluronamide；(3aS,4S,6R,6aR)-6-(6-amino-2-chloro-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid ethylamide；(3aS,4S,6R,6aR)-6-(6-amino-2-chloro-9H-purin-9-yl)-N-ethyl-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxamide；(3aR,4R,6S,6aS)-4-(6-amino-2-chloropurin-9-yl)-N-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide
• CAS: 120225-75-4
• 化学式: C₁₅H₁₉ClN₆O₄
• 分子量: 382.807
• InChiKey: CHPHKXXDQSHQKC-LOKDSWTASA-N

物化性质

• 熔点：
  210-212°C
• 溶解度：
  可溶于二甲基亚砜、甲醇、二甲基甲酰胺；溶解度50mg/L时为澄清无色溶液

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-氯-2,3-o-异亚丙基腺苷酸-5-n-乙基羧酰胺 在 盐酸 、 水 作用下， 以 甲醇 为溶剂， 以60%的产率得到2-chloro-adenosine-5'-N-ethylcarboxamide
  参考文献：
  名称：

  FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS

  摘要：

  检测方法通常包括形成均质的检测混合物，其中包括目标SAM利用蛋白、荧光检测分析物和测试化合物，孵育，并测量发射的FP或TR-FRET信号，以确定测试化合物-SAM利用蛋白结合的度量。检测混合物包括SAM利用蛋白和荧光检测分析物，在没有测试化合物的情况下与SAM利用蛋白结合。检测混合物还可以包括测试化合物。检测混合物的实施形式可以生成FP或TR-FRET信号特性，这些特性是测试化合物和检测分析物与SAM利用蛋白固有结合相互作用的函数。荧光检测分析物包括荧光团、共价连接物和SAM利用蛋白配体团，可以用于FP或TR-FRET检测来测量测试化合物的结合。

  公开号：

  US20120295283A1
• 作为产物：
  描述：

  5’-羧基-2-氯-2’-3’-O-异亚丙基腺苷酸 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-氯-2,3-o-异亚丙基腺苷酸-5-n-乙基羧酰胺
  参考文献：
  名称：

  2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands

  摘要：

  The synthesis and receptor-binding profiles at adenosine receptor subtypes for a series of 2-(arylalkylamino)-adenosin-5'-uronamides is described. Halogenated 2-phenethylamino analogues such as 3e show greater than 200-fold selectivity for the A2 receptor subtype on the basis of rat brain receptor binding. The general structure-activity relationship of this series of compounds is discussed both in terms of potency at A2 receptors as well as receptor subtype selectivity. It is possible to introduce a hydrophilic carboxyalkyl substituent to this series such as in CGS 21680A (3h) and still retain good potency and selectivity for A2 receptors. In addition, functional data in a perfused working rat heart model shows that these compounds possess full agonist properties at A2 receptors with 3h having a greater than 1500-fold separation between A2 (coronary vasodilatory) and A1 (negative chronotropic) receptor mediated events.

  DOI：

  10.1021/jm00169a015

文献信息

• Synthesis and Biological Activity of a New Series of <i>N</i>⁶-Arylcarbamoyl, 2-(Ar)alkynyl-<i>N</i>⁶-arylcarbamoyl, and <i>N</i>⁶-Carboxamido Derivatives of Adenosine-5‘-<i>N</i>-ethyluronamide as A₁ and A₃ Adenosine Receptor Agonists
  作者：Pier Giovanni Baraldi、Barbara Cacciari、Maria José Pineda de Las Infantas、Romeo Romagnoli、Giampiero Spalluto、Rosaria Volpini、Stefano Costanzi、Sauro Vittori、Gloria Cristalli、Neli Melman、Kyung-Sun Park、Xiao-duo Ji、Kenneth A. Jacobson

  DOI：10.1021/jm980147p

  日期：1998.8.1

  tested for affinity at A1 and A2A adenosine receptors in rat brain membranes and at cloned rat A3 receptors expressed in CHO cells. The derivatives contained the 5' substituent found in the potent, nonselective agonist 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofuranuronamide++ + (NECA). While the carboxamido derivatives (9-13) showed affinity for A1 receptors, the urea derivatives (30-45) showed

  一系列新的 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofurauronamide++ +-在嘌呤 6 位带有 N-芳基脲或 N-芳基甲酰胺基团已经合成了在 2 位与卤素或炔基链结合的 N-芳基脲和 N-芳基脲，并测试了对大鼠脑膜中 A1 和 A2A 腺苷受体以及在 CHO 细胞中表达的克隆大鼠 A3 受体的亲和力。该衍生物包含在强效非选择性激动剂 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofuranuronamide++ (NECA) 中发现的 5' 取代基。虽然甲酰胺衍生物 (9-13) 对 A1 受体表现出亲和力，但尿素衍生物 (30-45) 对 A3 腺苷受体亚型表现出不同程度的亲和力和选择性。特别是在 6 位带有对磺酰氨基苯基脲的衍生物，与参考化合物 1-
• Synthesis of Photoreactive 2-Phenethylamine Derivatives - Synthesis of Adenosine Derivatives Enabling Functional Analysis of Adenosine Receptors by Photoaffinity Labeling
  作者：Yuta Murai、Katsuyoshi Masuda、Yui Ogasawara、Lei Wang、Yasuyuki Hashidoko、Yasumaru Hatanaka、So Iwata、Takuya Kobayashi、Makoto Hashimoto

  DOI：10.1002/ejoc.201201657

  日期：2013.4

  compounds, and the synthesis of its photoreactive derivatives to allow the analysis of biological functions is reported. This allowed us to synthesise ligands for adenosine receptors, which have many functional roles in biology and have been extensively studied for their many roles in maintaining homeostasis. Adenosine is one of the most common biochemical compounds, but photoaffinity labeling has not yet

  2-苯乙胺是众所周知的许多生物活性化合物的亚结构，据报道合成了其光反应衍生物以进行生物功能分析。这使我们能够合成腺苷受体的配体，这些配体在生物学中具有许多功能性作用，并且因其在维持体内平衡中的许多作用而被广泛研究。腺苷是最常见的生化化合物之一，但光亲和标记尚未用于研究腺苷受体。建立了用于生产可与腺苷受体一起使用的光反应性腺苷衍生物的合成方法，用于光团苯基叠氮化物和二苯甲酮。使用腺苷受体测定法确定引入光反应性组分的效果。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20090240045A1

  公开（公告）日：2009-09-24

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 , R 3 , R 4 and W are as defined herein.

  式(I)的化合物，或其立体异构体或药学上可接受的盐，以及它们的制备和用作药物，其中R1、R2、R3、R4和W的定义如本文所述。
• WO2007/121918
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis and Biological Evaluation of Novel 1-Deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9<i>H</i>-purin-9-yl]-<i>N</i>-ethyl-β-<scp>d</scp>-ribofuranuronamide Derivatives as Useful Templates for the Development of A_2B Adenosine Receptor Agonists
  作者：Pier Giovanni Baraldi、Delia Preti、Mojgan Aghazadeh Tabrizi、Francesca Fruttarolo、Romeo Romagnoli、Maria Dora Carrion、Luisa Carlota Lopez Cara、Allan R. Moorman、Katia Varani、Pier Andrea Borea

  DOI：10.1021/jm061170a

  日期：2007.1.1

  The lack of molecules endowed with selective and potent agonistic activity toward the hA(2B) adenosine receptors has limited the studies on this pharmacological target and consequently the evaluation of its therapeutic potential. We report the design and the synthesis of the first potent (EC50 in the nanomolar range) and selective hA(2B) adenosine receptor agonists consisting of 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]-9H-purin-9-yl]-N-ethyl-beta-D-ribofuranuronamide derivatives. The concurrent effect of 6-substitution of the purine nucleus with a ((hetero)arylcarbonyl)hydrazino function and a 2-chloro substitution has been investigated in such NECA derivatives.